Vaxcellbio launches global co-development program in MM

South Korean immune-oncology company Vaxcellbio revealed it has signed a strategic memorandum of understanding (MOU) with Canadian biotechnology company Myellama to jointly develop a novel multiple myeloma therapy based on the National Research Council Canada's (NRC) next-generation NK cell engager technology.

The project establishes a four-party global collaboration involving the National Research Council Canada (NRC), the University of Ottawa, Myellama, and Vaxcellbio. The partnership combines the NRC's proprietary NK cell engager technology, the University of Ottawa's scientific expertise, Myellama's commercialization capabilities, and Vaxcellbio's allogeneic NK cell platform, GMP manufacturing expertise, and clinical development capabilities.